Rebecca Senter, PhD

Dr. Senter joined Axial in January 2022, bringing expertise in drug discovery and extensive experience leading non-clinical pharmacology, pharmacokinetics, and toxicology efforts to identify and validate therapeutic targets and drive development programs to IND and through clinical development. Prior to Axial, Dr. Senter held roles of increasing responsibility at Flexion Therapeutics, most recently as Director, Non-clinical and Translational Research. She completed her postdoctoral fellowship at the Massachusetts Institute of Technology (MIT) in the Picower Institute of Learning and Memory. Dr. Senter received her PhD in Pharmacology from Vanderbilt University’s School of Medicine, and a Bachelor of Science degree from St. Lawrence University.